Previous 10 | Next 10 |
IQVIA™ (NYSE: IQV), in scientific partnership with the U.S. Food and Drug Administration, will provide agile analytics from IQVIA’s CARE Project COVID-19 registry to support better understanding of how people in the community are affected by exposure to the coronavirus. IQ...
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its third-quarter financial results before the market opens on Tuesday, October 20, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings re...
Patients are seeing the benefits of biosimilars in the form of lower out-of-pocket costs, depending on their insurance plan design Recent biosimilar launches of bevacizumab, trastuzumab and rituximab are set to reach nearly 60% volume share by the end of their second year on t...
IQVIA™ (NYSE: IQV) today announced that its electronic Clinical Outcome Assessment (eCOA) solution, an advanced-study build and execution platform that optimizes real-time, direct-from-patient data collection, has been selected as the winner of the Fierce Innovation Awards – Lif...
There is considerable interest in healthcare stocks due to coronavirus. Beyond the pandemic, the best long-term opportunities lie with companies that are doing the most innovative work. Companies such as Intuitive Surgical (ISRG), Teladoc Health (TDOC), IQVIA Holdings (IQV), and Guardant Health...
This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins' 13F portfolio on a quarterly basis. It is based on Robbins' regulatory 13F Form filed on 08/14/2020. Please visit our Tracking Larry Robbins' Glenview Capital Management Portfolio artic...
RIM Smart is the modern regulatory information management solution built to increase speed, collaboration, efficiency and visibility IQVIA™ (NYSE: IQV) was recognized at the 18 th Annual American Business Awards ® , winning the Gold Stevie ® Award for Technical Innovat...
This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 08/17/2020. Please visit our Tracking Dan Loeb’s Third Point Portfoli...
Insider buying increased last week with insiders purchasing $172.17 million of stock compared to $88.83 million in the week prior. Selling also increased significantly with insiders selling $5.71 billion of stock last week compared to $1 billion in the week prior. With many companies already r...
IQVIA™ (NYSE: IQV) today announced that Nancy Dreyer, chief scientific officer and senior vice president, Real World Solutions, has been awarded PharmaVOICE magazine’s Red Jacket honor after she was recognized multiple times as a PharmaVOICE 100. IQVIA’s Deepa Desai, vi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...